554 related articles for article (PubMed ID: 31889610)
1. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
Griffin JM; Maurer MS
Trends Cardiovasc Med; 2021 Jan; 31(1):59-66. PubMed ID: 31889610
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
Rubin J; Maurer MS
Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
[TBL] [Abstract][Full Text] [Related]
3. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
[TBL] [Abstract][Full Text] [Related]
4. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society.
Grzybowski J; Podolec P; Holcman K; Gawor-Prokopczyk M; Jankowska E; Kostkiewicz M; Dąbrowska-Kugacka A; Lipowska M; Mazurkiewicz Ł; Rajtar-Salwa R; Rubiś P; Straburzyńska-Migaj E; Szczygieł J; Mitkowski P
Kardiol Pol; 2023; 81(11):1167-1185. PubMed ID: 37768101
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Amyloidosis Treatment.
Stern LK; Patel J
Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
[TBL] [Abstract][Full Text] [Related]
7. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality.
Donnellan E; Wazni OM; Saliba WI; Baranowski B; Hanna M; Martyn M; Patel D; Trulock K; Menon V; Hussein A; Aagaard P; Jaber W; Kanj M
J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2427-2432. PubMed ID: 31515942
[TBL] [Abstract][Full Text] [Related]
8. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy.
Vaishnav J; Brown E; Sharma K
Prog Cardiovasc Dis; 2024; 82():113-124. PubMed ID: 38246305
[TBL] [Abstract][Full Text] [Related]
9. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M
J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539
[TBL] [Abstract][Full Text] [Related]
10. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
[TBL] [Abstract][Full Text] [Related]
11. Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis.
Law S; Fontana M; Gillmore JD
Cardiol Clin; 2021 Aug; 39(3):389-402. PubMed ID: 34247752
[TBL] [Abstract][Full Text] [Related]
12. Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease.
Smiley DA; Rodriguez CM; Maurer MS
Cardiol Clin; 2022 Nov; 40(4):541-558. PubMed ID: 36210137
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of transthyretin-related amyloidosis cardiomyopathy.
Teng C; Li P; Bae JY; Pan S; Dixon RAF; Liu Q
Clin Cardiol; 2020 Nov; 43(11):1223-1231. PubMed ID: 32725834
[TBL] [Abstract][Full Text] [Related]
14. The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective.
Apostolou EA; Fontrier AM; Efthimiadis GK; Kastritis E; Parissis J; Kanavos P
Hellenic J Cardiol; 2023; 73():73-80. PubMed ID: 37201632
[TBL] [Abstract][Full Text] [Related]
15. Transthyretin Cardiac Amyloidosis and Novel Therapies to Treat This Not-so-rare Cause of Cardiomyopathy.
Capustin M; Frishman WH
Cardiol Rev; 2021 Sep-Oct 01; 29(5):263-273. PubMed ID: 34397539
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cardiac transthyretin amyloidosis: an update.
Emdin M; Aimo A; Rapezzi C; Fontana M; Perfetto F; Seferović PM; Barison A; Castiglione V; Vergaro G; Giannoni A; Passino C; Merlini G
Eur Heart J; 2019 Dec; 40(45):3699-3706. PubMed ID: 31111153
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implication of relative regional strain ratio in cardiac amyloidosis.
Senapati A; Sperry BW; Grodin JL; Kusunose K; Thavendiranathan P; Jaber W; Collier P; Hanna M; Popovic ZB; Phelan D
Heart; 2016 May; 102(10):748-54. PubMed ID: 26830665
[TBL] [Abstract][Full Text] [Related]
19. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
[TBL] [Abstract][Full Text] [Related]
20. Transthyretin amyloid cardiomyopathy.
Garcia-Pavia P; Domínguez F; Gonzalez-Lopez E
Med Clin (Barc); 2021 Feb; 156(3):126-134. PubMed ID: 33138983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
